601 Lexington Avenue, 31st Floor
New York, NY 10022

+1 212 277 4032

Local Litigation Star

Adam is co-head of Freshfields’ firmwide global investigations practice, based in New York. He represents clients facing government investigations and related civil litigation. Clients in a broad range of industries rely on Adam to defend them in investigations conducted by the US DOJ, SEC and state attorneys general in matters involving alleged violations of the Foreign Corrupt Practices Act, insider trading, tax fraud and accounting fraud.  

Adam works regularly with other Freshfields lawyers around the world in defending multi-jurisdictional investigations, developing compliance and training programs tailored to the global regulatory regimes faced by clients and conducting due diligence regarding bribery and other risks in corporate transactions. 

Adam served as Assistant United States Attorney in the Criminal Division of the US Attorney’s Office for the Southern District of New York, serving as Deputy Chief and Chief Appellate Attorney. 

Adam received a JD degree, magna cum laude, from Harvard Law School and an undergraduate degree, magna cum laude, from Harvard University. 

In addition to his recognition by Benchmark Litigation as a “Litigation Star” for White Collar Crime, Adam is ranked by Chambers for White Collar Crime and Government Investigations. 


Adam’s recent representations include:

  • IFF in a cross-border investigation into allegations of improper payments at a recently acquired subsidiary, including communicating with relevant governmental authorities. An international engineering company in internal reviews of corruption allegations and in discussions with multilateral development banks.
  • Insurance Corporation of Barbados Limited in securing the DOJ’s first declination with disgorgement under the FCPA Corporate Enforcement Policy.
  • Zurich Insurance Group in securing a non-prosecution agreement with the US DOJ Tax Division memorializing DOJ’s decision not to prosecute Zurich for any US tax-related offense in connection with cross-border sales of insurance products to US customers.
  • Bristol-Myers Squibb in securing a settlement with the SEC, resolving a five-and-a-half year investigation into the company’s relationships with healthcare professionals in China and other countries around the world – the DOJ declined to pursue criminal charges in a related investigation.


Updated Sep 2021